Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment

Patients Who Create a Blink Health Account Will Receive a Free, One-Year Supply of Three Most Prescribed Generic Type-2 Diabetes Medications: Metformin, Glipizide and Pioglitazone --Until Funds Are Exhausted

$10 Million Commitment Represents Savings to Consumers of up to $80 Million

Blink Health Also Offers 40% Discount on Eli Lilly Insulins Through First-of-Its-Kind Access Program

Blink Health Logo

News provided by

Blink Health

Jun 07, 2017, 12:23 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, June 7, 2017 /PRNewswire/ -- Blink Health, America's leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health's website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.

Blink Health #TreatType2 B-Roll
Blink Health #TreatType2 B-Roll
#TreatType2 Announcement
#TreatType2 Announcement
Blink Health #TreatType2 B-Roll
#TreatType2 Announcement

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/

As part of Blink Health's ongoing commitment to support people who are living with diabetes, the #TreatType2 program is designed to help the largest population of people managing this condition. Of the nearly 29 million Americans with diabetes, approximately 95 percent have been diagnosed with type 2.1

Blink Health will provide the free medications to everyone until it has committed to spending $10 million on the medications.  Any patient with a prescription for any or all of these three medications is eligible to receive medication for free. There is no cost to join Blink Health, and medication can be picked up at over 57,000 pharmacies nationwide, including Walmart, CVS, Rite-Aid, Target, and most independent pharmacies and grocers. 

The $10 million commitment is based on Blink's cost to purchase the medication and represents savings for consumers of up to $80 million, based on the retail prices of these medications for one year.

"Diabetes is a growing epidemic that affects 1 in 11 Americans, and Blink Health is committed to doing all it can to help patients manage this chronic illness," said Geoffrey Chaiken, Co-Founder and CEO of Blink Health. "We have seen far too many people who are struggling to afford prescription medication, and we've launched this program to help address the problem one patient at a time."

In April, Blink Health raised $90 million to drive innovations that accelerate its mission of making prescription medications affordable and transparently priced for everyone in the U.S.  With this $10 million commitment, Blink Health is using a substantial portion of these funds to directly help hundreds of thousands of people living with diabetes, who have health care costs 2.3 times greater, on average, than those without diabetes.2  

Chaiken added, "Blink Health is committed to supporting people with diabetes through the #TreatType2 program and through our groundbreaking insulin discount program with many of Eli Lilly's insulin products.  If you have diabetes – or if you know someone who does – sign up for Blink Health today. When you use Blink Health, you are joining a growing network of Americans who are tired of overpaying for their medications. Together, we are able to negotiate with pharmacies to determine one low price for each medication that is accepted at over 57,000 pharmacies nationwide.  The more people who join the 'Blink Health Nation,' the better our overall discounts will be." 

Information About Diabetes 

Diabetes is a chronic condition in which the body's ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates (foods that become sugar in the body) and elevated levels of glucose (digested sugar) in the blood and urine. Diabetes is categorized as type 1,  aka juvenile diabetes, or type 2, which starts later in life. Untreated diabetes creates blood vessel damage, poor circulation that can lead to loss of limbs, as well as blindness and other grave consequences. The vast majority of people today have type-2 diabetes, which is treated primarily with medications that regulate blood sugar. People born with type-1 diabetes must take insulin to regulate their blood sugar. 

Information About Discounted Insulin Available Through Blink Health 

Blink Health is also working on solutions to lower the price of insulin. As announced in December 2016, Blink Health and Eli Lilly and Company (NYSE: LLY) have entered into a first-of-its-kind access program to offer a 40 percent discount on Lilly insulins, including Humalog, one of the most widely prescribed branded insulin medications. Blink Health is pursuing similar arrangements with other pharmaceutical and healthcare companies to offer discounted medication and supplies. 

Attendance at American Diabetes Association 77th Scientific Sessions

Representatives of Blink Health will attend the annual American Diabetes Association 77th Scientific Sessions, starting Friday, June 9, where clinical advances will be announced. Healthcare providers in attendance who are interested in learning more about Blink Health and the #TreatType2 program can visit Blink Health at the San Diego Convention Center, Booth #1655.   

Information About the #TreatType2 Program 


What:

A free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone in their most common dosages: 



MEDICATION

STRENGTH

FORM


metformin hcl

500 MG

TABLET


metformin hcl

800 MG

TABLET


metformin hcl

1000 MG

TABLET


pioglitazone hcl

15 MG

TABLET


pioglitazone hcl

30 MG

TABLET


pioglitazone hcl

45 MG

TABLET


glipizide

5 MG

TABLET


glipizide

10 MG

TABLET





Who:

Any Blink Health member with a prescription for the medications.  Patients who are not already a member must create an account at BlinkHealth.com. 


When:

Registration for the program begins June 7. Registration must be completed by September 12, 2017.  The program will end before this date if members sign up for more than $10 million of the covered medications. 


Where:

The Blink Health website or free mobile app 


Why:

To help patients afford treatment for type-2 diabetes and bring transparency and lower drug costs to all Americans.


Please refer to the Blink Health website for complete terms and conditions.


Patients with questions about Blink Health or the #TreatType2 program can call  

(855) 776-0404 or e-mail: [email protected]. 


About Blink Health  
Founded in 2014, Blink Health is a technology platform that enables consumers to access the medications they need at prices they can afford at over 57,000 pharmacies nationwide. Blink's website and free mobile app allow users to purchase their medications online and pick them up at their local retailer for up to 90% off the average retail price. Blink Health groups patients together to leverage their purchasing power and secure significantly lower prices for the most-prescribed medications in America.  

Follow us on Facebook and Twitter: 

1 Source:  Centers for Disease Control and Prevention, Diabetes: At a Glance 2016, available at: https://www.cdc.gov/chronicdisease/resources/publications/aag/pdf/2016/diabetes-aag.pdf
2 Source: American Diabetes Association, The Staggering Cost of Diabetes, available at: http://www.diabetes.org/diabetes-basics/statistics/infographics/adv-staggering-cost-of-diabetes.html

SOURCE Blink Health

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.